Skip to main content
Equibles
TEVA logo

TEVA · Teva Pharmaceutical Industries Ltd

Track TEVA — free

Use TEVA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about TEVA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$37.61 -0.31 (-0.82%)
Market Cap
$44.19B
Shares
1.17B

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$37.92 Open$37.70 Day$37.07–38.06 52W close$18.04–38.10 Avg vol 30d5.5M Short int35.7M · 3.1% float · 6.6d Short vol41% Last earningsJul 29, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 29

Up next

Next earnings call
Oct 28, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 29, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
      Market backdrop VIX 15.2 · calm Equity put/call 0.64
      Technical
      price trend
      Strong Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +18%
      above
      Price vs 50-day avg +11%
      above
      RSI (14) 66
      neutral
      MACD trend Positive
      52-week position 99%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +9%
      trailing
      6-month return +19%
      trailing
      YTD return +22%
      this year
      Relative strength +7%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $34 › 200d $32 — 50d above 200d
      Institutional flow Accumulating
      +3% holders QoQ · +83 funds added
      Insider flow Distributing
      Net -$692.9K over 90 days · 100% sells
      Short interest Rising
      3.06% of float · ▲ +3.9% MoM · 6.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      677 holders — near 3-yr high, broad support
      Squeeze score 60
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +4%
      Y/Y
      Gross margin 52%
      expanding
      EPS growth +183%
      Y/Y
      Free cash flow $1.1B
      Valuation P/E 62.2
      in line
      Buyback $2.1B
      authorized
      Balance sheet $25.3B
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 40%
      annualized · 1-yr
      Max drawdown −22%
      past year
      ATR 2.7%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 2
      Latest guidance · from the 8-K filed Jul 29, 2026
      Revenues · 2026 $16.5B – $16.85B
      prior FY $17.26B midpoint −3.4% Y/Y
      Non-GAAP operating income · 2026 Non-GAAP $3.8B – $4B
      Adjusted EBITDA · 2026 $4.23B – $4.53B
      Non-GAAP diluted EPS · 2026 Non-GAAP $1.91 – $2.11
      Prior guidance period ended · from the 8-K filed Nov 5, 2025
      Revenues · 2025 $16.8B – $17B
      AJOVY revenue · 2025 $630M – $640M
      AUSTEDO revenue · 2025 $2.05B – $2.15B
      Non‐GAAP diluted EPS · 2025 $2.55 – $2.65
      UZEDY revenue · 2025 $190M – $200M
      Non‐GAAP operating income · 2025 $4.4B – $4.6B
      Free cash flow · 2025 $1.6B – $1.9B
      Guided vs delivered · last 2 settled
      Revenues 2025
      guided $16.8B – $17B
      $17.26B Beat +2.1%
      Total revenue 2024
      guided $15.7B – $16.3B
      $16.54B Beat +3.4%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Buy
      0 · 3 · 4
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +18% Bullish
      Price vs 50-day avg
      +11% Bullish
      RSI (14)
      66 Neutral
      MACD trend
      Positive Bullish
      52-week position
      99% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $34 › 200d $32 — 50d above 200d
      Institutional flow Accumulating
      +3% holders QoQ · +83 funds added
      Insider flow Distributing
      Net -$692.9K over 90 days · 100% sells
      Short interest Rising
      3.06% of float · ▲ +3.9% MoM · 6.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      677 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $18 Now $38 · 99% Range high $38
      vs 200-day avg +18% vs 50-day avg +11%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      AJOVY exit market share (subcutaneous injectable anti-CGRP class, total prescriptions) 32.5% the second quarter of 2026 —
      Anda revenues from third-party products $413M second quarter of 2026 —
      Average debt maturity 5.1 As of June 30, 2026 —
      Financial leverage 68% As of June 30, 2026 —
      Fully diluted share count 1.19B As of June 30, 2026 —
      Non-GAAP gross profit margin non-GAAP 54.2% Six months ended June 30, 2026 —
      Short-term debt portion 27% As of June 30, 2026 —
      Total prescriptions (trailing twelve months) 237M the second quarter of 2026 —
      Total U.S. generic prescriptions share 6.1% the second quarter of 2026 —
      Debt $16.63B as of March 31, 2026 —
      Gross profit margin 46.4% Q1 2026 —
      Non-GAAP operating income non-GAAP $956M the first quarter of 2026 —
      Gross debt $16.8B FY 2025 —
      Net debt $13.3B FY 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Drug Manufacturers - Specialty & Generic — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      TEVA
      Teva Pharmaceutical Industries Ltd
      this stock
      		$44.19B +21.5% +4.3% 62.2 3.1%
      JHPCY
      Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
      		 $66.37B — — — 0.0%
      TAK
      Takeda Pharmaceutical Co Ltd
      		 $58.22B +16.9% — — 0.1%
      GALDY
      Galderma Group AG/ADR
      		 $49.41B +2.3% — — 0.0%
      HLN
      Haleon plc
      		 $44.77B +0.6% — — 0.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      677
      % held
      65.3%
      Net QoQ
      +55.8M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      319
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      35.7M
      Days to cover
      6.6d
      Change
      +1.3M sh
      View
      Short Volume
      Short vol %
      41%
      As of
      Aug 27, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      26.8K
      Value
      $808.7K
      As of
      Jul 23, 2026
      View
      Off-Exchange
      Off-exchange %
      47.5%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$692.9K
      Buyers / Sellers
      0 / 4
      Buyers Sellers
      View
      Congressional Trades Buy
      Member
      Alan Armstrong
      Amount
      $1.0K–$15.0K
      Traded
      Mar 30, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $17.3B
      Net income (FY)
      $1.4B
      EPS diluted
      $1.21
      View
      Buybacks
      Authorized
      $2.1B
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 29, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $680.3K
      Shares
      18.6K
      Filed
      Aug 17, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 29, 2026
      View
      Investor Relations
      Latest news
      U.S. FDA Accepts Teva’s New Drug…
      Published
      Aug 19, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      TEVA +1.2% +9.3% +19.4% +8.3% +21.5%
      SPY -0.4% +5.0% +12.4% +2.6% +12.3%
      vs SPY +1.6% +4.2% +7.0% +5.8% +9.2%

      Capital returns

      Buyback program · as of Dec 31, 2017
      Authorized
      $2.10B
      Spent (derived)
      —
      Remaining
      —

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 818686 CUSIP 881624209 13F (30d) 519 filings 518 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)